SEC Tracker
Get the app
SILO · XBRL financial data

Silo Pharma financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (SILO's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021†Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Revenue41—72727272
Cost of revenue—566644
Cost of goods and services sold176—————
Gross profit(135)6666666628
Research and development266941,2868452,3682,161
Selling, general and administrative50163227390——
General and administrative121—————
Total operating expenses2,4382,8113,6943,9224,7724,308
Other operating income (expense)—2710———
Operating income (loss)(2,573)(2,744)(3,628)(3,856)(4,706)(4,281)
Interest income—————0
Interest expense0025537
Other income (expense)230271————
Income tax expense (benefit)—25————
Net income (loss)(3,038)3,904(3,909)(3,701)(4,393)(4,228)
Earnings per share, basic USD per share(0.05)0.04—(1.20)(1.19)(0.50)
Earnings per share, diluted USD per share(0.05)0.04—(1.20)(1.19)(0.50)
Weighted average shares, basic thousands of shares65,95594,8662,2843,0803,6808,382
Weighted average shares, diluted thousands of shares65,95595,9222,2843,0803,6808,382
  • † Share count changed about 1/31 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal years (SILO's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021†Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Cash and cash equivalents1,1289,83711,3673,5243,9064,749
Short-term investments———4,1413,1752,110
Inventory33—————
Prepaid and other current assets2411451361631209
Total current assets1,42710,40211,5727,6817,1117,388
Total assets1,42710,49011,6437,7467,4127,605
Accrued liabilities——20———
Total current liabilities1424904367761,656650
Total liabilities1461,4281,3021,5692,3781,300
Accumulated deficit(5,762)(3,263)(7,171)(10,872)(15,265)(19,492)
Total stockholders' equity1,2819,06210,3416,1775,0346,305
Total liabilities and equity1,42710,49011,6437,7467,4127,605
Common shares outstanding (cover page) thousands of shares85,17798,6723,1592,8444,48414,167
  • † Share count changed about 1/31 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal years (SILO's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021†Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Net income (loss)(3,038)3,904(3,909)(3,701)(4,393)(4,228)
Stock-based compensation756395578872907117
Net cash from operating activities(1,157)(2,278)(3,498)(3,224)(3,834)(4,661)
Net cash from investing activities397,19387(4,147)974644
Proceeds from issuing common stock2,116—4,941—1,673—
Net cash from financing activities2,1353,7944,941(471)3,2424,860
  • † Share count changed about 1/31 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Silo Pharma3,2770*(782)*1.6M6.7 quarters 10-QJun 30, 2026
Skinvisible452.2*5.4M— 10-QJun 30, 2026
Xenetic Biosciences6,472661(875)*2.3M7.4 quarters 10-QJun 30, 2026
Adia Nutrition128485(109)*94.4M1.2 quarters 10-QJun 30, 2026
Viskase Holdings7,74795,279454*14.3M— 10-QSep 30, 2026
Aspira Women's Health47717(2,010)*46.6M0.2 quarters 10-QJun 30, 2026
Creative Medical Technology Holdings8,7140(1,472)*6.6M5.9 quarters 10-QJun 30, 2026
Target Group141,381(223)*617.0M0.1 quarters 10-QJun 30, 2026
Soligenix9,811not reported(1,707)*21.8M5.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.